Key facts
- It has raised $1.9M; the latest was Seed Round ($1.9M) in Mar 2026.
- Notable investors include Scottish Enterprise, Twin Path Ventures, GU Holdings, University of Glasgow.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for TileBio
- ·The full record, as it builds
Funding rounds
No funding rounds for TileBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TileBio
Provider of AI pathology foundation models intended to transform clinical diagnostics and accelerate the discovery of new biomarkers and therapies. The company offers an AI-learned visual language of tissue, allowing for the comprehensive interpretation of complex pathological data with unprecedented accuracy, enabling customers to achieve earlier, precise disease detection and to significantly accelerate biomedical and pharmaceutical research efforts worldwide.
- Sector
- Healthcare
- HQ
- Glasgow, United Kingdom
- Founded
- 2025
- Employees
- 6
- Website
- tilebio.com/
- Ownership
- Privately Held (backing)
TileBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TileBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TileBio in its N-PORT filings yet. We sweep new filings monthly.